ALDOA Expression in Bladder Urothelial Carcinoma

August 9, 2024 updated by: Merna Hesham John, Assiut University

Immunohistochemical Expression and Prognostic Significance of ALDOA in Bladder Urothelial Carcinoma.

  1. Study the immunohistochemical expression of ALDOA in bladder urothelial cancer.
  2. Correlate between ALDOA expression in specimens and different cilnicopathological factors.
  3. Correlate between ALDOA expression and urothelial cancer prognosis and survival.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

Bladder cancer is the 7th most prevalent malignancy and the 13th cause of cancer related death worldwide1. In Egypt, it's the third most common tumor2.

The most common histologic subtype of bladder cancer is urothelial carcinoma3. Bladder cancer is divided according to absence or presence of muscle invasion into non-muscle invasive bladder cancer and muscle invasive bladder cancer 3.

Despite the advance in diagnosis and development of therapeutic options of urothelial cancer, the recurrence and progression rate remains high4.

The conventional histopathological evaluation of urothelial cancer is vital for diagnosis and prediction of patient's prognosis. However, it doesn't fully reflect the biological behavior of the tumor or the clinical outcome of the patient5.

Under hypoxic conditions, cancer cells produce ATP by glycolysis, which provide energy for tumor proliferation and dissemination6,7. Glycolytic enzymes are abnormally activated in cancer cells8,9. Thus, several studies have identified glycolytic enzymes or related metabolic pathways as potential drug targets. One of the typical glycolytic enzymes is Aldolase A (ALDOA) 6 which is the most abundant glycolytic enzyme detected in tumors10.

Several studies have identified ALDOA as an oncogene in different types of malignancy 6,8,10-12. The oncogenic potential of ALDOA contributed to its ability to stimulate DNA synthesis and accelerate S phase in tumor cell cycle6-8.

In addition, studies have shown that ALDOA promotes tumor cell invasion by negative regulation of E-cadherin and by activation of MAPK, AKT and EGFR signaling pathways7,11,13.

Thus, increased expression of ALDOA in tumor predicts a bad prognosis and poor survival of patients13-15.

Study Type

Observational

Enrollment (Estimated)

50

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Merna Hesham John, Demonstrator
  • Phone Number: +201289824116 +201070019195
  • Email: mernahesham@aun.edu.eg

Study Contact Backup

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

N/A

Sampling Method

Non-Probability Sample

Study Population

The study will be conducted using formalin fixed paraffin embedded blocks of fifty cases of urothelial carcinomas . These blocks will be obtained from laboratory archives of the Pathology Department, Assiut University Hospital, Faculty of Medicine. Clinical data for this study will be obtained from laboratory archives of the pathology department, Assiut University Hospital, Assiut University.

Description

Inclusion Criteria:

  • All cases diagnosed as bladder urothelial cancer with known follow-up data and presence of muscle proper detected in the specimens.

Exclusion Criteria:

  1. Subtypes of bladder cancer other than urothelial carcinoma subtype.
  2. Cases of urothelial carcinoma without known follow up data.
  3. Cases of urothelial carcinoma without muscle proper detected in the specimen.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Evaluate the immunohistochemical expression of ALDOA in bladder urothelial carcinoma.
Time Frame: Baseline
Microscopic examination of bladder urothelial carcinoma spicemens and staining them with ALDOA marker
Baseline

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Evaluate relation between ALDOA expression and cilnicopathological features and patient survival.
Time Frame: Baseline
Correlate between ALDOA expression and the different clinicopathological factors of patients and their survival.
Baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Assiut University

Investigators

  • Study Director: Dalia Elsers, Professor, Head of Pathology Department

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

September 1, 2024

Primary Completion (Estimated)

July 1, 2025

Study Completion (Estimated)

August 1, 2025

Study Registration Dates

First Submitted

August 9, 2024

First Submitted That Met QC Criteria

August 9, 2024

First Posted (Actual)

August 13, 2024

Study Record Updates

Last Update Posted (Actual)

August 13, 2024

Last Update Submitted That Met QC Criteria

August 9, 2024

Last Verified

August 1, 2024

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Bladder immunohistochemistry

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Bladder Urothelial Carcinoma

Clinical Trials on Immunohistochemistry

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Chile

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe